CDC Logo Skip Top Nav
 CDC Home PageSearch the CDCHealth Topics A though Z
Division of Tuberculosis Elimination
About DTBE Upcoming Events Site Map CDC en Espanol Contact Us
Skip the Contents menu


Skip the Resources menu


U.S. Department of Health and Human Services

Fact Sheets

Return to Fact Sheets Main Menu
(PDF - 46k)

BCG Vaccine
Last Updated: April 2006


BCG, or bacille Calmette-Guérin, is a vaccine for tuberculosis (TB) disease. BCG is used in many countries with a high prevalence of TB to prevent childhood tuberculous meningitis and miliary disease. However, BCG is not generally recommended for use in the United States because of the low risk of infection with Mycobacterium tuberculosis, the variable effectiveness of the vaccine against adult pulmonary TB, and the vaccine’s potential interference with tuberculin skin test reactivity. The BCG vaccine should be considered only for very select persons who meet specific criteria and in consultation with a TB expert.


Children. BCG vaccination should only be considered for children who have a negative tuberculin skin test and who are continually exposed, and cannot be separated from, adults who

  • Are untreated or ineffectively treated for TB disease (if the child cannot be given long-term treatment for infection); or
  • Have TB caused by strains resistant to isoniazid and rifampin.

Health Care Workers. BCG vaccination of health care workers should be considered on an individual basis in settings in which

  • A high percentage of TB patients are infected with M. tuberculosis strains resistant to both isoniazid and rifampin;
  • There is ongoing transmission of such drug-resistant M. tuberculosis strains to health care workers and subsequent infection is likely; or
  • Comprehensive TB infection-control precautions have been implemented but have not been successful.

Health Care Workers considered for BCG vaccination should be counseled regarding the risks and benefits associated with both BCG vaccination and treatment of latent TB infection (LTBI).


Immunosuppressed Persons. BCG vaccination should not be given to persons who are immunosuppressed (e.g., persons who are HIV-infected) or who are likely to become immunocompromised (e.g., persons who are candidates for organ transplant).

Pregnant Women. BCG vaccination should not be given during pregnancy. Even though no harmful effects of BCG vaccination on the fetus have been observed, further studies are needed to prove its safety.

Testing for TB in BCG-Vaccinated Persons

Many foreign-born persons have been BCG-vaccinated. BCG vaccination may cause a positive reaction to the tuberculin skin test (TST), which may complicate decisions about prescribing treatment. Despite this potential for BCG to interfere with test results, the TST and the QuantiFERON®-TB Gold test (QFT-G) are not contraindicated for persons who have been vaccinated with BCG. The presence or size of a TST reaction in these persons does not predict whether BCG will provide any protection against TB disease. Furthermore, the size of a TST reaction in a BCG-vaccinated person is not a factor in determining whether the reaction is caused by LTBI or the prior BCG vaccination.

Treatment for LTBI in BCG-Vaccinated Persons

Treatment of LTBI substantially reduces the risk that TB infection will progress to disease. Careful assessment to rule out the possibility of TB disease is necessary before treatment for LTBI is started. Evaluation of TST reactions in persons vaccinated with BCG should be interpreted using the same criteria for those not BCG-vaccinated. Persons in the following high-risk groups should be given treatment for LTBI if their reaction to the TST is ≥5 mm of induration:

  • HIV-infected persons
  • Recent contacts to a TB case
  • Persons with fibrotic changes on chest radiograph consistent with old TB
  • Patients with organ transplants
  • Persons who are immunosuppressed for other reasons (e.g., taking the equivalent of >15 mg/day of prednisone for 1 month or longer, taking TNF-a antagonists)

In addition, persons in the following high-risk groups should be considered for treatment of LTBI if their reaction to the TST is ≥ 10 mm of induration:

  • Recent arrivals (<5 years) from high-prevalence countries
  • Injection drug users
  • Residents and employees of high-risk congregate settings (e.g., correctional facilities, nursing homes, homeless shelters, hospitals, and other health care facilities)
  • Mycobacteriology laboratory personnel
  • Persons with clinical conditions that place them at high-risk for developing TB disease (e.g., diabetes)
  • Children <4 years of age, or children and adolescents exposed to adults in high-risk categories

Persons with no known risk factors for TB may be considered for treatment of LTBI if their reaction to the tuberculin test is ≥15 mm of induration. However, targeted skin testing programs should only be conducted among high-risk groups. All testing activities should be accompanied by a plan for follow-up care for persons with TB infection or disease.

Additional Information

CDC. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1998; 47 (No. RR-13).

CDC. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: a joint statement by ACET and the Advisory Committee on Immunization Practices. MMWR 1996; 45 (No. RR-4).

World Health Organization. Issues Relating to the Use of BCG in Immunization Programmes-A Discussion Document (PDF) (1999).

Last Reviewed: 05/18/2008
Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention


Back to Top of Page

If you would like to order any of the DTBE publications please visit the online order form.

You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348

Skip Bottom Nav Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA |
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: